BioCentury
ARTICLE | Clinical News

Agios falls on Phase I data

November 10, 2015 2:49 AM UTC

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) dropped $10.79 (14%) to $65.04 on Monday after it reported one partial response among 55 patients in a Phase I study of AG-120 to treat advanced solid tumors with isocitrate dehydrogenase 1 (IDH1) mutations. The results were presented at a plenary session of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

Agios now has made a round-trip since Oct. 27, when it surged $16.09 (25%) to $80.94 on news it would present the results. ...